NEONC TECHNOLOGIES HOLDINGS, INC.
NTHINext catalyst
Perillyl alcohol
Glioblastoma Multiforme
Get an email about NTHI's next catalysts
Track NEONC TECHNOLOGIES HOLDINGS (NTHI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (earnings, conference, Phase 2 readout).See the timeline
5 upcoming, 1 past
NTHI Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.41 | FQ end Sep/2026 | Call: tbd
Conference Presentation - NEO100
For Recurrent WHO Grade III/IV IDH1-mutant astrocytoma. NeOnc Technologies announced it will present two posters on intranasal NEO100 and oral NEO212 at the Society for Neuro-Oncology annual meeting on November 13, 2026 in Philadelphia. The NEO100 poster describes durable remission and prolonged survival in recurrent IDH1-mutant astrocytoma, while the NEO212 poster covers Phase 1 safety, PK, and early activity signals.
SourcePerillyl alcohol Phase 2 Est. Readout
Estimated primary completion for Perillyl alcohol trial (NCT02704858) in Glioblastoma Multiforme. Topline data typically follows completion by weeks to months.
SourceNEO100 Phase 2 Est. Readout
Primary completion for NEO100 trial (NCT05023018) in Residual, Progressive or Recurrent Grade II or III Meningioma
SourceNEO212 Oral Capsule Phase 2 Est. Readout
Estimated primary completion for NEO212 Oral Capsule trial (NCT06047379) in Diffuse Astrocytoma, IDH-Mutant. Topline data typically follows completion by weeks to months.
SourceHow NTHI's past catalysts played out
Market Overview
Stock performance and key metrics
NEO212 Oral Capsule
Diffuse Astrocytoma, IDH-Mutant
Perillyl alcohol
Glioblastoma Multiforme
NEO100
Residual, Progressive or Recurrent Grade II or III Meningioma
FOLFIRI Protocol
Diffuse Astrocytoma, IDH-Mutant
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NEO212 Oral Capsule | Phase 2 | Diffuse Astrocytoma, IDH-Mutant | - | - |
Perillyl alcohol | Phase 2 | Glioblastoma Multiforme | - | - |
NEO100 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | - | - |
FOLFIRI Protocol | Phase 2 | Diffuse Astrocytoma, IDH-Mutant | - | - |
Frequently asked questions
What is in NEONC TECHNOLOGIES HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in NEONC TECHNOLOGIES HOLDINGS, INC.'s (NTHI) pipeline across Phase 2. Its lead program is NEO100 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NEONC TECHNOLOGIES HOLDINGS, INC.'s next FDA catalyst?→
NEONC TECHNOLOGIES HOLDINGS, INC.'s (NTHI) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NTHI biotech catalysts?→
Add NTHI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NEONC TECHNOLOGIES HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.